TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

NEXTERONE

AMIODARONE HYDROCHLORIDE
Approved 2008-12-24
1
Indication
--
Phase 3 Trials
17
Years on Market

Details

Status
Prescription
First Approved
2008-12-24
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: AMIODARONE HYDROCHLORIDE

NEXTERONE Approval History

Loading approval history...

What NEXTERONE Treats

2 indications

NEXTERONE is approved for 2 conditions since its original approval in 2008. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Ventricular Fibrillation
  • Ventricular Tachycardia
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NEXTERONE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

NEXTERONE Premixed Injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. NEXTERONE Premixed Injection is an antiarrhythmic agent indicated for treatment and prophylaxis of ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy.

NEXTERONE Patents & Exclusivity

Latest Patent: Mar 2029

Patents (9 active)

US7635773 Expires Mar 13, 2029
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.